RBI Granted 'Fast Track' Designation by FDA, Validating Its Direct-to-Brain Stem Cell Therapy for Alzheimer's Disease
Designation Follows Encouraging Phase I Results and FDA Clearance of a Multi-Center, Double-Blind, Placebo-Controlled Phase II Trial NEWPORT BEACH, CA, UNITED STATES, June 15, 2026 /EINPresswire.com/ -- Regeneration Biomedical, Inc. (RBI), a clinical- …